Shivani Nanda
Broad Institute · 116 works · 2,540 citations · h-index 17
Top works
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
- Abstract P6-15-01: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)
- Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.
- A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).
- MA09.07 Activity of Larotrectinib in TRK Fusion Lung Cancer
- TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
- Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis
- Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
- biomarkers Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR ) HER2- metastatic breast cancer (MBC)
- WormPaths: Caenorhabditis elegans metabolic pathway annotation and visualization
- Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)
- Modeling tissue‐relevant Caenorhabditis elegans metabolism at network, pathway, reaction, and metabolite levels
- A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
- Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.
- Larotrectinib efficacy and safety in adult TRK fusion cancer patients.
- A meta-analysis to indirectly compare the safety and efficacy of PD-1 and PD-L1 antibodies across solid tumors using a Bayesian hierarchical model.
- Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
- Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients